Linked Life Data

15600300

Source:http://linkedlifedata.com/resource/pubmed/id/15600300

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15600300rdf:typepubmed:Citationlld:pubmed
pubmed-article:15600300lifeskim:mentionsumls-concept:C1704858lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C2825965lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0009013lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0536940lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0020964lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C1413787lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0062863lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C1707520lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15600300lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15600300pubmed:dateCreated2004-12-16lld:pubmed
pubmed-article:15600300pubmed:abstractTextNY-ESO-1 is one of the most immunogenic cancer antigens known to date, eliciting spontaneous immune responses in approximately 50% of patients with NY-ESO-1+ cancers. Spontaneous CD4+ and CD8+ T cell responses were found in patients with detectable NY-ESO-1 serum antibody, indicating an integrated type of immune response induced by NY-ESO-1+ malignancies. A close association between spontaneous NY-ESO-1 immunity and the HLA-DP4 allele was suggested in a recent study. To address these results, we assessed the NY-ESO-1 antibody and HLA-DP4 status of 102 patients with NY-ESO-1+ malignancies. However, no correlation between HLA-DP4 and NY-ESO-1 immunity was found. To explore the role of HLA-DP4-restricted CD4+ T cells in cancer immunity, we established HLA-DP4- restricted NY-ESO-1-specific CD4+ T cell clones by limiting dilution and repeated stimulation with NY-ESO-1 peptide p157-170 from NY-ESO-1 seropositive patients. A subset of CD4+ T cell clones was reactive with naturally processed NY-ESO-1 presented by autologous DCs that were pulsed with recombinant NY-ESO-1 protein, lysates of NY-ESO-1-expressing tumor cell lines, or transduced with recombinant NY-ESO-1 viral constructs in ELISPOT assays. Three different CD4+ T cell clones were used to mediate the specific lysis of allogeneic HLA-DP4+ Epstein-Barr virus-transformed B cells (EBV-B) pulsed with NY-ESO-1 p157-170. The Th1 phenotype and effector functions of the CD4+ T cell clones described here provide an important rationale for the activation of antigen-specific CD4+ T cells along with CD8+ T cells in cancer vaccination strategies.lld:pubmed
pubmed-article:15600300pubmed:languageenglld:pubmed
pubmed-article:15600300pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:citationSubsetIMlld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15600300pubmed:statusMEDLINElld:pubmed
pubmed-article:15600300pubmed:monthDeclld:pubmed
pubmed-article:15600300pubmed:issn1424-9634lld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:ChenYao-Tseng...lld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:HuarteEduardo...lld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:KarbachJuliaJlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:KnuthAlexande...lld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:JägerElkeElld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:ArandMichaelMlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:JägerDirkDlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:OldLloyd JLJlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:RitterGerdGlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:BenderArminAlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:GnjaticSachaSlld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:AtanackovicDj...lld:pubmed
pubmed-article:15600300pubmed:authorpubmed-author:SkipperJonath...lld:pubmed
pubmed-article:15600300pubmed:issnTypeElectroniclld:pubmed
pubmed-article:15600300pubmed:day16lld:pubmed
pubmed-article:15600300pubmed:volume4lld:pubmed
pubmed-article:15600300pubmed:ownerNLMlld:pubmed
pubmed-article:15600300pubmed:authorsCompleteYlld:pubmed
pubmed-article:15600300pubmed:pagination15lld:pubmed
pubmed-article:15600300pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:meshHeadingpubmed-meshheading:15600300...lld:pubmed
pubmed-article:15600300pubmed:year2004lld:pubmed
pubmed-article:15600300pubmed:articleTitleHLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.lld:pubmed
pubmed-article:15600300pubmed:affiliationII. Medizinische Klinik, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany.lld:pubmed
pubmed-article:15600300pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15600300pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed